Pembrolizumab + Lenvatinib + Oxaliplatin + Capecitabine + Leucovorin (or Levoleucovorin) + 5-FU
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Conditions
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Trial Timeline
Dec 30, 2020 → Mar 31, 2026
NCT ID
NCT04662710About Pembrolizumab + Lenvatinib + Oxaliplatin + Capecitabine + Leucovorin (or Levoleucovorin) + 5-FU
Pembrolizumab + Lenvatinib + Oxaliplatin + Capecitabine + Leucovorin (or Levoleucovorin) + 5-FU is a phase 3 stage product being developed by Eisai for Advanced/Metastatic Gastroesophageal Adenocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04662710. Target conditions include Advanced/Metastatic Gastroesophageal Adenocarcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04662710 | Phase 3 | Active |
Competing Products
20 competing products in Advanced/Metastatic Gastroesophageal Adenocarcinoma